We have previously shown that hemopoietic stem cell transplant (HSCT) recipients can be stratified on day+7 as having low, intermediate or a high risk of transplant-related mortality (TRM). With the aim of reducing TRM and GVHD, intermediate and high-risk patients (n = 170) were randomized to receive anti-thymocyte globulin (ATG, thymoglobuline) on day+7 (n = 84) or no treatment (n = 86) (controls). There was a reduction of TRM from 35% in controls to 29% in ATG patients (P = 0.3), of acute GVHD III-IV from 15 to 5% (P = 0.02) and of chronic GVHD from 26 to 11% (P = 0.03); survival was comparable. The predictive value of the day+7 score on TRM was confirmed for controls (19 vs 42% for intermediate vs high risk, respectively, P = 0.03), whereas ATG abrogated this predictive effect (29 vs 29%). ATG reduced GVHD (P = 0.006) in high-risk patients, but not in patients with an intermediate risk. In conclusion, we confirm that TRM can be predicted on the basis of day+7 laboratory values, after alternative donor HSCT; in high-, but not intermediate-risk patients, the administration of ATG on day+7 reduces GVHD. These results may represent a platform for risk-adapted post transplant immune modulation. Bone Marrow Transplantation (2010) 45, 385-391; doi:10.1038/bmt.2009.151; published online 6 July 2009
Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants
CICERI , FABIO;
2010-01-01
Abstract
We have previously shown that hemopoietic stem cell transplant (HSCT) recipients can be stratified on day+7 as having low, intermediate or a high risk of transplant-related mortality (TRM). With the aim of reducing TRM and GVHD, intermediate and high-risk patients (n = 170) were randomized to receive anti-thymocyte globulin (ATG, thymoglobuline) on day+7 (n = 84) or no treatment (n = 86) (controls). There was a reduction of TRM from 35% in controls to 29% in ATG patients (P = 0.3), of acute GVHD III-IV from 15 to 5% (P = 0.02) and of chronic GVHD from 26 to 11% (P = 0.03); survival was comparable. The predictive value of the day+7 score on TRM was confirmed for controls (19 vs 42% for intermediate vs high risk, respectively, P = 0.03), whereas ATG abrogated this predictive effect (29 vs 29%). ATG reduced GVHD (P = 0.006) in high-risk patients, but not in patients with an intermediate risk. In conclusion, we confirm that TRM can be predicted on the basis of day+7 laboratory values, after alternative donor HSCT; in high-, but not intermediate-risk patients, the administration of ATG on day+7 reduces GVHD. These results may represent a platform for risk-adapted post transplant immune modulation. Bone Marrow Transplantation (2010) 45, 385-391; doi:10.1038/bmt.2009.151; published online 6 July 2009I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
